- This event has passed.
Faculty Candidate Talk: Abbas Rizvi, PhD
March 14 @ 9:00 am - 10:00 am
Speaker: Abbas Rizvi, PhD
Associate Research Scientist
Zuckerman Mind Brain Behavior Institute at Columbia University
Talk Title: “Multimodal Interrogation of the Human Spinal Cord”
Location: Room 1441 Genetics/Biotech, 425 Henry Mall or via Zoom
About the Speaker:
Abbas Rizvi is a molecular neuroscientist at the Zuckerman Mind Brain Behavior Institute at Columbia University. Abbas received his bachelor’s degree in Molecular Biology and Physics from the University of California at Berkeley and his doctorate from Harvard University with Erin O’Shea. His postdoctoral studies were conducted at Columbia University with Tom Maniatis and Richard Axel. At the Zuckerman Institute, Abbas and his group are spearheading the generation of an atlas of the adult human spinal cord, as part of the Chan Zuckerberg Initiative’s Seed Networks for the Human Cell Atlas. The approaches he will discuss offer a unique perspective regarding physiologically relevant cellular states occurring within the mammalian central nervous system during both health and disease.
About the Cluster Hire:
UW’s Cluster Hiring Initiative was launched in 1998 as an innovative partnership between the university, state and the Wisconsin Alumni Research Foundation (WARF). In its first phase, the initiative authorized nearly 50 “clusters” and nearly 150 new faculty through several rounds of hiring. In 2017, phase two of the Cluster Hiring Initiative was authorized with a goal of supporting at least 12 clusters.
A proposal by several Waisman Center investigators for a Functional Genetics/Genomics of Neurodevelopmental and Neurodegenerative Diseases cluster at the Waisman Center was selected by the UW-Madison Cluster Hire Initiative.
New faculty hires who are part of the Functional Genetics/Genomics of Neurodevelopmental and Neurodegenerative Diseases cluster at the Waisman Center will help develop a pipeline of discovery that begins with patients in the clinics and ends with new approaches for treatments or therapies. This cycle of translational research would start with identifying patient-specific genetic variants, and then continue through experimental studies to confirm whether these variants truly cause disease. Ultimately, new panels for diagnosis and new approaches for treatment may be discovered.
For Zoom Participation Contact:
Clark Kellogg at email@example.com